Gerda Egger

Dr. Gerda Egger

Department of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria
+1
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2004 in Nature
Verified
Journal Article
Closed access
PDF file
Gerda EggerGerda Egger
Gerda Egger
GLGangning Liang
Gangning Liang
AAAna Aparicio
Ana Aparicio
PJPeter A. Jones
Peter A. Jones

1 June 2006 in Cancer Cell
Verified
Journal Article
Closed access
YSYoshimasa Saito
Yoshimasa Saito
GLGangning Liang
Gangning Liang
Gerda EggerGerda Egger
Gerda Egger
JFJeffrey M. Friedman
Jeffrey M. Friedman
JCJody C. Chuang
Jody C. Chuang
PJPeter A. Jones
Peter A. Jones

3 May 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GLGangning Liang
Gangning Liang
JLJoy C. Y. Lin
Joy C. Y. Lin
VWVivian Wei
Vivian Wei
CYChristine Yoo
Christine Yoo
JCJonathan C. Cheng
Jonathan C. Cheng
PJPeter A. Jones
Peter A. Jones
Almost 1-2% of the human genome is located within 500 bp of either side of a transcription initiation site, whereas a far larger proportion (≈25%) is potentially transcribable by elongating RNA polymerases. This observation raises the question of how the genome is packaged into chromatin to allow start sites to be recognized by the regulatory machinery at the same time as transcription initiation, but not elongation, is blocked in the 25% of intragenic DNA. We developed a chromatin scanning technique called ChAP, coupling the chromatin immunoprecipitation assay with arbitrarily primed PCR, which allows for the rapid and unbiased comparison of histone modification patterns within the eukaryotic nucleus. Methylated lysine 4 (K4) and acetylated K9/14 of histone H3 were both highly localized to the 5′ regions of transcriptionally active human genes but were greatly decreased downstream of the start sites. Our results suggest that the large transcribed regions of human genes are maintained in a deacetylated conformation in regions read by elongating polymerase. Common models depicting widespread histone acetylation and K4 methylation throughout the transcribed unit do not therefore apply to the majority of human genes.

2 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EGEinav Nili Gal-Yam
Einav Nili Gal-Yam
Gerda EggerGerda Egger
Gerda Egger
LILeo Iniguez
Leo Iniguez
HHHeather Holster
Heather Holster
SESteingrímur Einarsson
Steingrímur Einarsson
ATAmos Tanay
Amos Tanay
Epigenetic reprogramming is commonly observed in cancer, and is hypothesized to involve multiple mechanisms, including DNA methylation and Polycomb repressive complexes (PRCs). Here we devise a new experimental and analytical strategy using customized high-density tiling arrays to investigate coordinated patterns of gene expression, DNA methylation, and Polycomb marks which differentiate prostate cancer cells from their normal counterparts. Three major changes in the epigenomic landscape distinguish the two cell types. Developmentally significant genes containing CpG islands which are silenced by PRCs in the normal cells acquire DNA methylation silencing and lose their PRC marks (epigenetic switching). Because these genes are normally silent this switch does not cause de novo repression but might significantly reduce epigenetic plasticity. Two other groups of genes are silenced by either de novo DNA methylation without PRC occupancy (5mC reprogramming) or by de novo PRC occupancy without DNA methylation (PRC reprogramming). Our data suggest that the two silencing mechanisms act in parallel to reprogram the cancer epigenome and that DNA hypermethylation may replace Polycomb-based repression near key regulatory genes, possibly reducing their regulatory plasticity.

1 November 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
GZGordin Zupkovitz
Gordin Zupkovitz
JTJulia Tischler
Julia Tischler
MPMarkus Posch
Markus Posch
ISIwona Sadzak
Iwona Sadzak
KRKatrin Ramsauer
Katrin Ramsauer
CSChristian Seiser
Christian Seiser
Remote monitoring (RM) receives a Class I: Level of Evidence: A recommendation for the follow-up of patients with implantable cardioverter-defibrillators, positioning the technology as standard of care. RM is often seen and sold as a plug-and-play technology, whereas fundamental differences exist in the philosophy and conception of the 5 main RM systems. The capabilities and limitations of the different RM systems need to be understood and taken into account when the decision is made to remotely manage an individual patient. The purpose of this review is to provide to the cardiologist practical information about RM systems’ specificities with respect to the different technical and clinical alerts. Clinically based indications and programming suggestions are provided. Central Illustration

1 February 2009 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YSYoshimasa Saito
Yoshimasa Saito
JFJeffrey M. Friedman
Jeffrey M. Friedman
YCYoshitomo Chihara
Yoshitomo Chihara
Gerda EggerGerda Egger
Gerda Egger
JCJody C. Chuang
Jody C. Chuang
GLGangning Liang
Gangning Liang